Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Therapeutic Gases in Biomedicine: Updates on Nitric Oxide and Beyond

Andrabi SM., Sharma NS., Rather IG., Shahriar SMS., Xie J.

Narrative Review on Chronic Inflammation, published in Adv Sci (Weinh) (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Adv Sci (Weinh) (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41858245
PMCID
PMC13104097
DOI
10.1002/advs.202521942

Abstract (original English)

Gaseous mediators are increasingly recognized as critical regulators of human physiology and pathology, offering unique therapeutic opportunities that are fundamentally constrained by challenges in controlled delivery, spatial targeting, and biological specificity when harnessed through advanced delivery technologies. Among them, nitric oxide (NO) has emerged as a central player. Recent advancements have transitioned from conventional donor-based systems with limited control over dose and localization to wearable gas-delivery platforms capable of real-time, patient-specific dosing and frequently coupling with embedded diagnostic functionalities for dynamic feedback and precision control. Importantly, the therapeutic scope of gas biology is expanding beyond NO to encompass other clinically relevant and emerging gases, including O 2 , CO, H 2 S, H 2 , CO 2 , SO 2 , and Xe. These gases exhibit multifaceted biological effects ranging from cytoprotection and vasoregulation to antimicrobial and anti-inflammatory actions, thereby necessitating innovative material-based and bioresponsive delivery strategies that can interface dynamically with biological systems. By critically assessing progress in material platforms, responsive release mechanisms, and multimodal delivery approaches, this review bridges fundamental gas biology with clinically translatable therapeutic design. We further

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansNitric OxideGasesDrug Delivery Systems

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research